8-K: Avenue Therapeutics Faces Delisting from Nasdaq Due to Equity Deficiency

Avenue Therapeutics, Inc. has been notified by Nasdaq that its common stock will be delisted due to non-compliance with minimum stockholders' equity requirements.

Summary

• Avenue Therapeutics received notification from Nasdaq on March 17, 2025, that its common stock will be delisted.
• The delisting is due to the company's failure to maintain the minimum stockholders' equity of $2,500,000, as required by Nasdaq Listing Rule 5550(b)(1).
• Trading of the company's common stock on Nasdaq will be suspended at the open of trading on March 19, 2025.
• The company's stock is expected to begin trading on the OTC Markets system under the ticker symbol ATXI on March 19, 2025.
• Avenue Therapeutics plans to continue filing periodic reports with the SEC.
• The company acknowledges that there is no assurance its stock will continue to trade on the OTC market or that sufficient trading volume will exist.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting from Nasdaq, indicating financial distress and potential challenges for the company's future.

Positives

• The company plans to continue filing its required periodic reports and other filings with the SEC.
• The company's common stock is expected to begin trading on the OTC Markets system effective with the open of the markets on March 19, 2025.

Negatives

• Avenue Therapeutics failed to regain compliance with Nasdaq's rules regarding minimum stockholders' equity.
• The company's common stock will be delisted from the Nasdaq Capital Market.
• There is no assurance that the company's common stock will continue to trade on the OTC market or that sufficient trading volume will exist.

Risks

• Trading on the OTC Market system carries potential risks, including liquidity constraints and limited regulatory oversight.
• The company's ability to continue as a going concern is subject to substantial doubt.
• The company needs substantial additional funding, which may not be available on acceptable terms.
• The company faces risks related to regulatory approval of its product candidates and potential product liability claims.

Future Outlook

The company plans to continue filing its required periodic reports with the SEC and expects its common stock to begin trading on the OTC Markets system. However, there is no assurance that its common stock will continue to trade on this market, whether broker-dealers will continue to provide public quotes of its common stock on this market, or whether the trading volume of its common stock will be sufficient to provide for an efficient trading market for existing and potential holders of its common stock.

Industry Context

Delisting from a major exchange like Nasdaq can negatively impact a company's visibility, investor confidence, and access to capital. Companies facing delisting often attempt to regain compliance or seek alternative listing venues.

Comparison to Industry Standards

• Companies like Diffusion Pharmaceuticals and Lipocine Inc. have faced similar delisting challenges due to low stock prices or market capitalization.
• These companies often explore options such as reverse stock splits, capital raises, or strategic acquisitions to regain compliance.
• Avenue Therapeutics' move to the OTC Markets is a common step for companies facing delisting, but it typically results in lower trading volumes and increased volatility.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the delisting and potential liquidity constraints.
• Employees may face uncertainty regarding the company's future prospects.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• The company's common stock is expected to begin trading on the OTC Markets system effective with the open of the markets on March 19, 2025.
• The Company plans to continue to file its required periodic reports and other filings with the SEC.

Key Dates